Which has better earnings and valuation, ORGO or ARDX?

Organogenesis has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organogenesis $564.17M 0.52 $37.03M -$0.19 N/A Ardelyx $407.32M 3.11 -$61.60M -$0.23 N/A

Is ORGO or ARDX more profitable?

Organogenesis has a net margin of -0.84% compared to Ardelyx's net margin of -13.58%. Organogenesis' return on equity of 9.63% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Organogenesis -0.84% 9.63% 4.76% Ardelyx -13.58% -38.11% -11.85%

Does the media refer more to ORGO or ARDX?

In the previous week, Ardelyx had 2 more articles in the media than Organogenesis. MarketBeat recorded 4 mentions for Ardelyx and 2 mentions for Organogenesis. Ardelyx's average media sentiment score of 1.02 beat Organogenesis' score of 0.63 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORGO or CRVS?

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 2 mentions for Organogenesis. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Organogenesis' score of 0.63 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ORGO or CAPR?

In the previous week, Capricor Therapeutics had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Capricor Therapeutics and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.63 beat Capricor Therapeutics' score of 0.63 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capricor Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ORGO or SVRA more profitable?

Savara has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Organogenesis -0.84% 9.63% 4.76% Savara N/A -87.19% -66.42%

Does the media favor ORGO or SDGR?

In the previous week, Schrodinger had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Schrodinger and 2 mentions for Organogenesis. Schrodinger's average media sentiment score of 0.73 beat Organogenesis' score of 0.63 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Organogenesis (ORGO) Competitors

$2.28 +0.02 (+0.66%)

As of 11:14 AM Eastern

Compare

ORGO vs. ARDX, CRVS, CAPR, SVRA, and SDGR

Should you buy Organogenesis stock or one of its competitors? MarketBeat compares Organogenesis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organogenesis include Ardelyx (ARDX), Corvus Pharmaceuticals (CRVS), Capricor Therapeutics (CAPR), Savara (SVRA), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry.

How does Organogenesis compare to Ardelyx?

Organogenesis (NASDAQ:ORGO) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Organogenesis has a net margin of -0.84% compared to Ardelyx's net margin of -13.58%. Organogenesis' return on equity of 9.63% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Ardelyx	-13.58%	-38.11%	-11.85%

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Organogenesis has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

In the previous week, Ardelyx had 2 more articles in the media than Organogenesis. MarketBeat recorded 4 mentions for Ardelyx and 2 mentions for Organogenesis. Ardelyx's average media sentiment score of 1.02 beat Organogenesis' score of 0.63 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis currently has a consensus price target of $5.75, indicating a potential upside of 151.64%. Ardelyx has a consensus price target of $15.73, indicating a potential upside of 206.28%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Organogenesis has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.52	$37.03M	-$0.19	N/A
Ardelyx	$407.32M	3.11	-$61.60M	-$0.23	N/A

Summary

Organogenesis beats Ardelyx on 9 of the 17 factors compared between the two stocks.

How does Organogenesis compare to Corvus Pharmaceuticals?

Organogenesis (NASDAQ:ORGO) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Organogenesis has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Organogenesis has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.52	$37.03M	-$0.19	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Organogenesis presently has a consensus target price of $5.75, indicating a potential upside of 151.64%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 130.33%. Given Organogenesis' higher probable upside, research analysts plainly believe Organogenesis is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 2 mentions for Organogenesis. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Organogenesis' score of 0.63 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Organogenesis beats Corvus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Organogenesis compare to Capricor Therapeutics?

Organogenesis (NASDAQ:ORGO) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Organogenesis has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

In the previous week, Capricor Therapeutics had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Capricor Therapeutics and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.63 beat Capricor Therapeutics' score of 0.63 indicating that Organogenesis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis currently has a consensus price target of $5.75, indicating a potential upside of 151.64%. Capricor Therapeutics has a consensus price target of $53.67, indicating a potential upside of 160.43%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Organogenesis has higher revenue and earnings than Capricor Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.52	$37.03M	-$0.19	N/A
Capricor Therapeutics	$22.27M	53.59	-$105.04M	-$2.32	N/A

Capricor Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Capricor Therapeutics	N/A	-59.27%	-48.65%

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Organogenesis beats Capricor Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Organogenesis compare to Savara?

Organogenesis (NASDAQ:ORGO) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Organogenesis has higher revenue and earnings than Savara. Organogenesis is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.52	$37.03M	-$0.19	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Organogenesis presently has a consensus price target of $5.75, indicating a potential upside of 151.64%. Savara has a consensus price target of $10.14, indicating a potential upside of 77.48%. Given Organogenesis' higher possible upside, equities analysts plainly believe Organogenesis is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Organogenesis had 1 more articles in the media than Savara. MarketBeat recorded 2 mentions for Organogenesis and 1 mentions for Savara. Savara's average media sentiment score of 1.87 beat Organogenesis' score of 0.63 indicating that Savara is being referred to more favorably in the news media.

Company	Overall Sentiment
Organogenesis	Positive
Savara	Very Positive

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Savara has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Savara	N/A	-87.19%	-66.42%

Organogenesis has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Savara has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Summary

Organogenesis beats Savara on 9 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Schrodinger?

Organogenesis (NASDAQ:ORGO) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Organogenesis has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Schrodinger had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Schrodinger and 2 mentions for Organogenesis. Schrodinger's average media sentiment score of 0.73 beat Organogenesis' score of 0.63 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis has higher revenue and earnings than Schrodinger. Organogenesis is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.52	$37.03M	-$0.19	N/A
Schrodinger	$255.87M	4.72	-$103.26M	-$1.41	N/A

Organogenesis presently has a consensus target price of $5.75, indicating a potential upside of 151.64%. Schrodinger has a consensus target price of $20.25, indicating a potential upside of 23.89%. Given Organogenesis' higher probable upside, equities analysts plainly believe Organogenesis is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Organogenesis has a net margin of -0.84% compared to Schrodinger's net margin of -40.61%. Organogenesis' return on equity of 9.63% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Schrodinger	-40.61%	-30.85%	-15.32%

Summary

Organogenesis and Schrodinger tied by winning 8 of the 16 factors compared between the two stocks.

Get Organogenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGO vs. The Competition

Export

Metric	Organogenesis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$294.03M	$2.99B	$6.74B	$12.51B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-12.03	18.66	26.90	24.39
Price / Sales	0.52	822.95	587.69	117.46
Price / Cash	3.71	56.80	29.22	49.36
Price / Book	0.97	4.22	10.92	6.33
Net Income	$37.03M	$64.26M	$3.58B	$330.66M
7 Day Performance	-8.60%	-3.42%	-2.25%	-0.84%
1 Month Performance	-2.35%	2.26%	3.08%	-0.26%
1 Year Performance	-49.11%	20.47%	26.23%	19.99%

Organogenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGO Organogenesis	1.9046 of 5 stars	$2.29 +0.7%	$5.75 +151.6%	-47.2%	$294.03M	$564.17M	N/A	950
ARDX Ardelyx	3.3963 of 5 stars	$5.32 -0.3%	$15.73 +195.4%	+14.5%	$1.32B	$407.32M	N/A	90
CRVS Corvus Pharmaceuticals	2.9101 of 5 stars	$15.24 +0.5%	$33.33 +118.7%	+255.3%	$1.28B	N/A	N/A	30	News Coverage
CAPR Capricor Therapeutics	2.5552 of 5 stars	$22.11 -1.4%	$53.67 +142.8%	+169.8%	$1.28B	$22.27M	N/A	101
SVRA Savara	2.3938 of 5 stars	$6.21 +0.2%	$10.14 +63.2%	+140.2%	$1.28B	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organogenesis (ORGO) Competitors

ORGO vs. ARDX, CRVS, CAPR, SVRA, and SDGR

How does Organogenesis compare to Ardelyx?

Summary

How does Organogenesis compare to Corvus Pharmaceuticals?

Summary

How does Organogenesis compare to Capricor Therapeutics?

Summary

How does Organogenesis compare to Savara?

Summary

How does Organogenesis compare to Schrodinger?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organogenesis (ORGO) Competitors

ORGO vs. ARDX, CRVS, CAPR, SVRA, and SDGR

How does Organogenesis compare to Ardelyx?

Is ORGO or ARDX more profitable?

Do institutionals & insiders have more ownership in ORGO or ARDX?

Which has more volatility and risk, ORGO or ARDX?

Does the media refer more to ORGO or ARDX?

Do analysts rate ORGO or ARDX?

Which has better earnings and valuation, ORGO or ARDX?

Summary

How does Organogenesis compare to Corvus Pharmaceuticals?

Do institutionals and insiders believe in ORGO or CRVS?

Which has more risk and volatility, ORGO or CRVS?

Is ORGO or CRVS more profitable?

Which has better valuation & earnings, ORGO or CRVS?

Do analysts prefer ORGO or CRVS?

Does the media favor ORGO or CRVS?

Summary

How does Organogenesis compare to Capricor Therapeutics?

Which has more risk & volatility, ORGO or CAPR?

Does the media refer more to ORGO or CAPR?

Do analysts prefer ORGO or CAPR?

Which has higher earnings and valuation, ORGO or CAPR?

Is ORGO or CAPR more profitable?

Do institutionals & insiders believe in ORGO or CAPR?

Summary

How does Organogenesis compare to Savara?

Which has preferable valuation and earnings, ORGO or SVRA?

Do analysts prefer ORGO or SVRA?

Does the media refer more to ORGO or SVRA?

Do insiders & institutionals believe in ORGO or SVRA?

Is ORGO or SVRA more profitable?

Which has more volatility & risk, ORGO or SVRA?

Summary

How does Organogenesis compare to Schrodinger?

Which has more risk & volatility, ORGO or SDGR?

Do insiders and institutionals believe in ORGO or SDGR?

Does the media favor ORGO or SDGR?

Which has stronger earnings and valuation, ORGO or SDGR?

Do analysts recommend ORGO or SDGR?

Is ORGO or SDGR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools